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Abstract
Although treat-to-target has revolutionised the outcomes of patients with rheumatoid arthritis (RA) there is
emerging evidence that attaining the target of remission is insufficient to normalise patients’ quality of life, and
ameliorate the extra-articular impacts of RA. RA has a broad range of effects on patient’s lives, with four key
“extra-articular” impacts being pain, depression and anxiety, fatigue and rheumatoid cachexia. All of these are seen
frequently; for example, studies have reported that 1 in 4 patients with RA have high-levels of fatigue. Commonly
used drug treatments (including simple analgesics, non-steroidal anti-inflammatory drugs and anti-depressants)
have, at most, only modest benefits and often cause adverse events. Psychological strategies and dynamic and
aerobic exercise all reduce issues like pain and fatigue, although their effects are also only modest. The aetiologies
of these extra-articular impacts are multifactorial, but share overlapping components. Consequently, patients are
likely to benefit from management strategies that extend beyond the assessment and treatment of synovitis, and
incorporate more broad-based, or “holistic”, assessments of the extra-articular impacts of RA and their management,
including non-pharmacological approaches. Innovative digital technologies (including tablet and smartphone
“apps” that directly interface with hospital systems) are increasingly available that can directly capture patient-
reported outcomes during and between clinic visits, and include them within electronic patient records. These are
likely to play an important future role in delivering such approaches.
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Background
The current treatment paradigm for patients with
rheumatoid arthritis (RA) is “treat-to-target” (T2T) [1].
This involves measuring a patient’s disease activity, using
composite scores like the disease activity score on a
28-joint count (DAS28), and escalating disease-modifying
anti-rheumatic drug (DMARD) therapy until the targets
of remission, or low disease activity (LDA) are attained.
The T2T strategy is based on the extensive evidence that
patients attaining remission have better health related
quality of life (HRQoL) and function, and lower rates of
radiological damage, when compared to patients in higher
disease activity states [2–6].
RA has many impacts on patients’ lives not directly
addressed by reducing disease activity using T2T strat-
egies. Four key examples are [1] pain, [2] depression and
anxiety, [3] fatigue, and [4] muscle loss. Although con-
trolling disease activity and achieving remission benefits
patients it usually fails to normalise HRQoL [5, 7] and
ameliorate pain [8] and fatigue [9, 10]. This is particu-
larly true of those individuals with established disease,
with two independent studies showing that short-form
36 (SF-36) health profiles – measuring health across 8
domains, each of which is scored from 0 to 100, with
higher scores representing better health – are worse in
patients with established RA in remission, compared
with the normal general population (Fig. 1) [5, 7]. The
first study by Radner et al. [5], compared SF-36 health
profiles in 356 German RA patients at a single
time-point stratified by disease activity status (captured
using the simplified disease activity index) to those
observed in the healthy German population; lower
HRQoL was seen in all 8 domains in patients in remis-
sion compared with the healthy population. The second
study, by Scott et al. [7], compared SF-36 health profiles
in 205 English RA patients enrolled to the TACIT trial
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(of combination DMARDs vs. anti-TNF) at the trial
end-point of 12-months, stratified by disease activity
status (captured using the DAS28); lower HRQoL was
seen in all domains in patients in remission, with the ex-
ception of mental health. The impact of RA on HRQoL
is likely to be minimised by extending the focus of dis-
ease management beyond synovitis, to incorporate the
evaluation of issues like pain, depression and anxiety.
In this review we will provide an overview of pain, de-
pression and anxiety, fatigue, and muscle loss in patients
with RA. We have focussed on these four “extra-articu-
lar” impacts as they are a diverse group of features,
which have been studied in detail, are relatively
common, improve with readily available interventions,
have negative impacts on patients’ lives including
reducing their HRQoL, and cannot be resolved simply
by achieving remission. We will summarise their preva-
lence, aetiology, assessment tools, and treatment
strategies. We will also outline the ways in which they
can be assessed within routine practice settings.
Pain
Definition
The conventional definition of pain from the Inter-
national Association for the Study of Pain. defines it as
“an unpleasant sensory and emotional experience associ-
ated with actual or potential tissue damage, or described
in terms of such damage [11]”. This broad definition
reflects the multidimensional nature of pain, which is
purely subjective, harbours an emotional element, and
can occur in the absence of actual tissue damage. At the
same time, it is important to appreciate that there are
divergent views on how to define pain. For example,
McCaffery defined pain to be “whatever the experiencing
person says it is, existing whenever the experiencing per-
son says it does” [12].
Assessing pain
A broad range of patient reported outcome (PRO) in-
struments have been developed and used to capture pain
in patients with RA. Burkhardt and Jones have published
a detailed summary of their assessment of the key mea-
sures [13]. An overview of these is provided in Table 1.
They span quick and simple unidimensional instruments
of pain intensity such as the pain VAS [14], generic
multidimensional instruments such as the McGill Pain
Questionnaire [15, 16] (capturing information on many
pain dimensions across a range of adult populations),
and disease-specific instruments like the RA pain scale
(RAPS) [17] (gaining information on pain most relevant
to patients with RA).
The simplest to use within a busy, routine clinical
setting is the pain VAS [14]. This comprises one
horizontal or vertical line, commonly 10 cm long, that
has the verbal descriptors “no pain” and “pain as bad as
it could be” at either end (although variations in verbal
end-points are often observed). Patients place a line per-
pendicular to the VAS line at the point best representing
Fig. 1 Spydergrams Showing Impact of Attaining Remission on Short-Form 36 Health Profiles in Patients with Established RA. Panel A = SF-36
health profiles in German RA patients, stratified by disease activity status (captured using the simplified disease activity index) and compared
to the healthy German population. Panel B = SF-36 health profiles in 205 English RA patients enrolled to the TACIT trial at the end-point of
12-months, stratified by disease activity status (captured using the DAS28). PF = physical functioning, RP = role physical, BP = bodily pain;
GH = general health; VT = vitality; SF = social functioning, RE = role emotional; MH =mental health. Figures adapted with permission under the
creative commons attribution license from the original published papers [5, 7]
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their current pain, with the score ranging from 0 to 100
(if scored in mm). The pain VAS has been shown to
have high test-retest reliability in patients with RA,
although it is higher in literate (r = 0.94) than illiterate
(r = 0.71) people [18]. The optimal cut-off to define an
“acceptable” level of pain has been defined as ≤2.0 units,
and the minimal clinically important change for pain in
observational studies reported as being 1.1 units [19].
Whilst the pain VAS is easy to score and interpret, as it is
a unidimensional measure it cannot fully capture the
multidimensional nature of patients’ pain.
Prevalence in RA
Pain represents a key symptom in patients with RA. In
the earliest stages of the disease process, it is the domin-
ant reason why people initially seek a review by their
physician, with a recent qualitative study of patients with
newly diagnosed RA reporting pain to be central to their
symptom experience [20].
In patients with established RA, pain is also an import-
ant issue. In two multi-national RA patient surveys –
the “Good Days Fast” survey, which explored the impact
of RA on the lives of women, and the “Getting to Your
Destination Faster” survey, which explored patients’
treatment goals – pain was identified as being of para-
mount importance [21]. In the “Good Days Fast” survey,
from 1958 women surveyed, 63% reported experiencing
pain every day, with 75% taking analgesics. Despite the
high prevalence of pain, however, many patients
reported problems discussing it with their health care
provider, with 55% feeling too shy to talk about how
much pain they experienced, and 73% reporting they feel
like they are complaining when discussing their pain
symptoms. In the “Getting to Your Destination Faster”
survey, from the 1829 patients surveyed, 70% agreed that
pain relief was the most important aspect of their man-
agement. A further third survey, of 1024 patients with
RA in Norway, showed similar findings. In this study,
69% of patients reported pain as their preferred area for
improvement [22], despite which over one-third of
patients were not receiving analgesics. Taken together,
these three patient surveys provide good evidence that
improving pain is a crucial, patient-centred treatment
goal in RA.
Aetiology of RA pain
Pain in patients with RA is multifactorial. Synovitis,
systemic inflammation [23], and joint damage [24] all
play roles in both the initiation and perpetuation of pain.
However, pain also often occurs in the absence of
synovitis or joint damage, highlighting the importance of
peripheral sensitisation (hypersensitivity of the nocicep-
tive primary afferent neurons in the peripheral nervous
system) and central sensitisation (hyperexcitability of
nociceptive neurons in the central nervous system) [25].
High levels of pain are generally observed in patients
with highly active disease, and improve with the use of
intensive synthetic and biologic DMARD therapy [26].
Although reducing synovitis with intensive DMARD
treatment improves pain, in many patients clinically
significant levels of pain remain in the absence of
synovitis. This is demonstrated in an analysis of the
North American Brigham and Women’s Hospital RA Se-
quential study (BRASS), by Lee et al. [8]. In this analysis,
the 154 patients in DAS28-CRP defined sustained remis-
sion over 12 months were evaluated; 11.9% had clinically
Table 1 Key Methods to Assess Pain in Patients with Rheumatoid Arthritis
Measure Population Content Completion time
(minutes)
Scoring time
(minutes)
McGill Pain
Questionnaire [15, 16]
For use in adults with
chronic pain problems
78 words describing the sensory, affective and evaluative
aspects of pain, alongside a 5-point present pain intensity
scale.
5–15 1–2
Rheumatoid Arthritis
Pain Scale [17]
Adults with RA 24 items measuring descriptions of pain, it’s severity and
interference.
5 2
Pain Visual Analogue
Scale [14]
Any adult population Usually one horizontal line, measuring 10 cm, anchored
with verbal descriptors “no pain” and “pain as bad as it
could be”.
< 1 < 1
Verbal Descriptive
Scale [14]
Any adult population Similar to pain visual analogue scale, replacing whole
numbers with verbal descriptors of pain (e.g. no pain, slight
pain, mild pain, moderate pain, severe pain, very severe
pain, the most intense pain imaginable).
< 1 < 1
Numeric rating scale
[123]
Any adult population Segmented version of pain visual analogue scale, with
patients selecting a whole number (0–10 integers) that
best reflects their pain intensity
< 1 < 1
Short-Form 36 Bodily
pain [124]
Any adult population A 2-item scale in which patients rate: [1] the intensity of
their pain (6-point scale ranging from “none” to “very se-
vere”), and [2] extent to which pain interferes with their
work (5-point scale ranging from “not at all” to “extremely”)
< 2 1
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significant pain at baseline (defined as a multi-dimen-
sional health assessment (MDHAQ) pain score of ≥4)
and 12.5% after 1 year of follow-up. Pain scores were ob-
served to be significantly and positively associated with
fatigue and sleep disturbance (evaluated using the
MDHAQ), and significantly and negatively associated
with self-efficacy (evaluated using the arthritis
self-efficacy score). No significant association with in-
flammatory markers or seropositivity was reported.
Other studies have also reported pain scores above those
seen in the normal population in patients with RA in
remission [5, 7].
There is strong clinical and experimental evidence that
peripheral and central sensitisation play crucial roles in
RA-related pain. This has led to the use of the term
“fibromyalgic RA”, in which fibromyalgia and RA
co-exist in the same patient [27]. The prevalence of
co-existing fibromyalgia in people with RA is high; a
large study of 11,866 patients with RA identified 1731
(17.1%) as also having fibromyalgia, the presence of
which associated with increased medical costs, more se-
vere RA, and a worse HRQoL [28]. Animal studies pro-
vide further evidence for the role of pain pathway
aberrancies in inflammatory arthritis, with these seeming
to occur prior to the onset of clinical signs of synovitis.
Nieto et al. evaluated this issue in two separate studies
of female rodents with a collagen-induced arthritis. In
the first study, allodynia of the rodent hind paw devel-
oped concomitantly with articular inflammatory cell in-
filtration, activation of joint nociceptors, and spinal
microgliosis; these changes took place prior to the onset
of visible synovitis. When paw swelling finally developed,
a significant number of primary afferent neurons innerv-
ating tissues external to the joint were also activated
[29]. In the second study, they reported that mechanical
allodynia was evident prior to the development of visible
paw swelling, worsened as swelling developed, and was
associated with reactive spinal microgliosis [30].
Microglial cells are resident macrophages in the central
nervous system [31], which rapidly respond to a broad
range of stimuli. They appear critical to the development
of chronic pain and central sensitisation [32], with
activated microglia secreting pro-inflammatory and
pro-nociceptive mediators, such as TNF and IL-18,
which modulate synaptic transmission and pain [33, 34].
Whilst it is often perceived that joint damage is a con-
tributor to pain, the evidence for this is, at best, limited.
Sokka et al. evaluated the relationship between Larsen
scores and function (assessed using the health assess-
ment questionnaire (HAQ)) and pain (assessed using the
pain visual analogue scale (VAS)) in 141 patients with
established RA [35]. Larsen scores had a signification
association with HAQ (r = 0.277, P = 0.001) but not pain
VAS (r = 0.008, P = 0.929). Sarzi-Puttini et al. also
evaluated associations between cross-sectional pain VAS,
and disease characteristics and outcomes in 105 patients
with established RA [24]. In a multivariate regression
model, Larsen scores explained only 2.1% of the
variation in pain VAS.
Treatment of pain in RA
The multifactorial and multidimensional nature of pain
suggests that a multifaceted approach to its management
is needed that combines pharmacological strategies, with
psychological and physical therapies, which have been
demonstrated across a range of trials to have beneficial
effects on reducing RA pain.
DMARDs and biologics reduce pain in active RA, and
optimising immunosuppressive therapy to control RA is
important in this regard. In addition, both simple
analgesics such as paracetamol and non-steroid
anti-inflammatory drugs (NSAIDs) also reduce pain levels,
although their effects are generally small-to-modest.
Hazelwood et al. systematically reviewed the evidence for
the efficacy of paracetamol in inflammatory arthritis,
identifying 12 trials and 1 observational study [36]. There
was weak evidence of a benefit of paracetamol over pla-
cebo. However, most of the included studies were reported
20–50 years ago, and some evaluated atypical paracetamol
dosing (such as 2 g of paracetamol over 24-h [37]).
Additionally, they had high-risks of bias due to incomplete
reporting of details surrounding sequence generation, allo-
cation concealment, and blinding, alongside incomplete
outcome data with high dropout rates and lack of
intention-to-treat analysis. NSAIDs are commonly used in
patients with RA, with clinical trials supporting their
efficacy [38, 39]. Whilst clinicians and patients prefer to
use NSAIDs over paracetamol in RA, the relative analgesic
merits of NSAIDs compared with paracetamol are uncer-
tain [40].
Opiates are prescribed to a substantial minority of
patients with RA. One observational study from North
America found over one-third of RA patients used
opiates in some form [41]. In more than a tenth use was
chronic, with opiate use increasing in recent years.
However, there is limited evidence for their efficacy.
Whittle et al. systematically reviewed the literature for
trials comparing opiates vs. another intervention or
placebo in patients with RA. Eleven studies were identi-
fied, all of which were of a short duration (< 6 weeks).
Although opiates were more likely to improve the
patient-reported global impression of change in pain,
they were also more likely to cause adverse events, with
no difference in net efficacy after adjustment for adverse
events observed between opioids and placebo [42].
Tricyclic anti-depressants and neuromodulators (such
as nefopam) are also often used, particularly if patients
have poor sleep or fibromyalgic RA. As with opiates, the
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evidence supporting their efficacy is weak, with systematic
reviews reporting limited evidence that oral nefopam and
topical capsaicin are superior to placebo at reducing pain
in patients with RA [43], and inconclusive evidence about
the efficacy of tricyclic antidepressants [44].
When these limited benefits are weighed against the
toxicity profiles of these analgesics – with both paraceta-
mol and NSAIDs associating with an increased risk of
myocardial infarction, renal impairment, and upper GI
bleeds [45–47], and nefopam and tricyclic antidepres-
sants frequently causing side-effects – it appears vital to
ensure that patients are fully informed of the risks and
benefits of their analgesic treatment, and that they are
used cautiously, for the shortest duration possible, and
stopped if patients are failing to gain clinical benefit.
Exercise is encouraged in patients with RA, due to its
wide-ranging impacts on general health and well-being.
Exercise is defined as any activity that improves physical fit-
ness. It can vary in type and intensity. Several trials have
evaluated the impact of dynamic exercise (defined as activ-
ities with sufficient intensity, duration, and frequency to im-
prove stamina or muscle strength) on pain in RA [48]. A
systematic review reported small benefits on pain scores in
patients receiving short-term, land-based aerobic capacity
and muscle strength training, with patients receiving
dynamic exercise rating their pain to be 0.5 units lower (on
a 0–10 scale) at 12-weeks, compared to those not receiving
the intervention [48]. However, this change is below the
minimal clinically important difference for pain [49].
Psychological interventions are also a vital component
of managing chronic musculoskeletal pain. These focus
on empowering patients to self-manage their pain. Three
commonly employed psychological strategies comprise:
[1] stress management training, which helps patients
cope with functional problems resulting from RA; [2]
education, helping patients make informed decisions
about self-managing their condition; and [3]
cognitive-behavioural therapy (CBT), which teaches
patients methods to manage their pain. Knittle et al.
evaluated the effects of such face-to-face psychological
interventions by undertaking a systematic review and
meta-analysis of relevant randomised controlled trials.
Small, but statistically significant effects were seen on
improving physical activity, pain, disability and de-
pression at follow-up evaluations [50]. Similar findings
were reported in another systematic review of psycho-
logical interventions in RA, undertaken by Astin et al
[51]; it found significant but small pooled effect sizes
post-intervention for pain of 0.22.
Anxiety and depression
Definition
Anxiety disorders are defined by excess worry, hyper-
arousal and fear which is both counterproductive and
debilitating [52]. Its most extreme form is generalised
anxiety disorder (GAD), which is characterised by per-
sistently heightened tension and excessive worry about a
range of events, that contributes to impaired functioning
[53]. Depression is characterised by a persistently low
mood, and loss of interest or pleasure in most activities.
Depression may be associated with symptoms including
an altered appetite, poor sleep, fatigue, lack of concen-
tration and suicidal thoughts. The degree of depression
is determined by the number and severity of associated
symptoms, and any related functional impairment [54].
Prevalence in RA
Approximately 38% of patients with RA suffer from
depression [55]. The prevalence of anxiety is approxi-
mately half that of depression, and estimated to lie
between 13 and 20% [56, 57]. When this is compared to
the prevalence of depression and anxiety in the general
population (with the 2014 Adult Psychiatric Morbidity
Survey reporting that 5.9% and 3.3% of the adult English
population suffered from generalised anxiety disorder
and a depressive disorder, respectively) [58], it is clear
that patients with RA have a significantly increased
mental health burden.
Aetiology in RA
Margaretten et al. have previously provided a summary
of the multifactorial nature of reduced mental health in
RA [59]. It is likely that different factors contribute to
the initiation and perpetuation of depression in different
individuals. Characteristics that have been associated
with depression include low socioeconomic status [60],
co-morbidities [61, 62], pain [23], and disability [63, 64].
Systemic inflammation has also been linked with depres-
sion, leading to the proposal of the “cytokine hypothesis
of depression”, in which pro-inflammatory cytokines are
considered to be important mediators of this disorder
[65]. It remains to be determined, however, as to
whether such cytokines are causally involved in depres-
sion aetiology, or if they represent immunological reac-
tions to depressive disorders [65]. Additionally, in the
context of RA, the link between systemic inflammation
and the onset of depression is uncertain [23, 66].
The factors underlying the excess anxiety observed in
RA have received less attention than those of depression.
However, a recent review by Sturgeon et al. highlighted
the key issues [67]. Anxiety in RA is driven in part by
personal factors including social context combined with
the impact of ongoing pain and disability and the inflam-
matory process. The factors causing depression and anx-
iety in RA are very similar and often occur together in
individual patients.
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Impacts
Comorbid mental health problems in RA are associated
with worse patient outcomes. Several studies have re-
ported that poorer mental health associates with higher
levels of DAS28-defined disease activity, although this
appears to be driven by its relationship with the
“subjective” components of the DAS28 (the tender joint
count (TJC) and patient global assessment of disease
activity (PtGA)). Matcham et al.. performed a secondary
analysis of the CARDERA trial, reporting that the pres-
ence of persistent depression and anxiety associated with
higher DAS28 scores over time; exploring relationships
with the individual DAS28-components revealed the
association was restricted to the TJC and PtGA, with no
significant association seen between depression and
anxiety and the swollen joint count (SJC) and erythrocyte
sedimentation rate (ESR) [68]. Similarly, Cordingley et
al. reported a significant association between the
PtGA and the Hospital Anxiety and Depression Scale
(HADS) depression score in 322 RA patients awaiting
biologic therapy, but not the other DAS28 compo-
nents [69].
Depression has also been linked with increased mor-
tality in RA, with Ang et al.. reporting that amongst
1290 patients with RA observed over 18 years, the pres-
ence of clinical depression in the first 4 years of entry
into their clinical cohort provided a hazards ratio (HR)
on mortality of 2.2 (95% CI 1.2–3.9, P = 0.01) [70]. De-
pression also increases healthcare costs, with Michaud
et al. identifying the presence of depression to be a key
predictor of increased medical outpatient costs (out-
patient procedures, laboratory tests, and physician visits)
amongst 7527 RA patients, followed up over a 2-year
period [71].
Identifying anxiety and depression
Despite the detrimental impact of mental health disor-
ders on RA outcomes, rheumatologists and primary care
physicians do not routinely screen for the presence of
mental health issues in patients with RA. In the National
Health Service (NHS) this probably reflects a combin-
ation of time constraints within clinic appointments,
alongside uncertainties as to who is leading on this as-
pect of patient care (primary or secondary care clini-
cians). However, to improve the outcomes and HRQoL
of patients, the recognition and management of mood
problems in RA should be a healthcare priority. Re-
search from the Institute of Psychiatry in London has
both highlighted the relative absence of screening in
standard care for long-term conditions and shown it can
be readily achieved using simple digital assessment
methods [72].
One method to implement the routine screening of
mental health disorders in RA would be to incorporate
it within an annual review. This process is recommended
by the National Institute for Health and Care Excellence
(NICE), which advise an RA annual review that incorpo-
rates an assessment of mood. There are, however, several
problems implementing this recommendation. Firstly,
there is uncertainty as to where the annual review
should occur, and although the NHS Quality and Out-
comes Framework (QOF) – which focusses on improv-
ing the care of long-term diseases through financial
incentives to attain specific clinical targets [73] – incen-
tivises a primary-care based annual review of patients
with RA, 20% of GPs feel that this does not benefit their
patients [74]. Secondly, it is unclear how mental health
should be assessed within an annual review. Thirdly,
there is a lack of a standardised approach to the annual
review process, with cardiovascular and osteoporosis risk
assessments being undertaken more often than depres-
sion screening [74].
NICE guidelines for the identification of depression in
adults with chronic physical health problems [75],
suggest the most sensitive tools for case-finding are the
General Health Questionnaire (GHQ-28) and the
two-stem questions of the Patient Health Questionnaire
(PHQ-9) [75], with the latter often preferred due to their
ease of use. These two-stem questions comprise: [1]
during the last month, have you often been bothered by
feeling down, depressed or hopeless? and [2] during the
last month, have you often been bothered by having little
interest or pleasure in doing things?
International guidelines for identifying anxiety and
experience from the Institute of Psychiatry in London
suggests a similar approach can be taken to find patients
with significant anxiety [72, 76]. An abbreviated version
of the GAD-7 scale, the GAD-2, has been recommended
as a case-finding tool for anxiety. This asks two
questions: [1] during the last month, have you often
been bothered by feeling nervous, anxious or on edge?
and [2] during the last month, have you often been both-
ered by not being able to stop or control worrying? It
has a moderately high balance of sensitivity and specifi-
city for detecting clinically relevant anxiety [77].
Managing anxiety and depression in RA
NICE have produced guidelines for the management of
depression and generalised anxiety disorder in adults,
and also the management of depression in adults with
long-term physical health disorders. These recommend a
stepped care approach, outlined in Fig. 2, in order to
identify the most effective, and least intrusive interven-
tion [53, 54, 75]. If a person declines, or fails to benefit
from a treatment, they are offered an appropriate inter-
vention from the next step in the pathway.
Specific to patients with RA, only a handful of trials
have evaluated interventions to treat depression and
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anxiety. A recently published systematic literature review
has highlighted the paucity of data in this area [78]. This
reviewed literature from controlled trials of treatments
for depression and anxiety in RA. Only 8 trials were
identified, all of which evaluated interventions for
depression; no trials evaluated anxiety treatments. Of
these, only one trial assessed medications that are often
used in contemporary practice (comparing the selective
serotonin reuptake inhibitor, paroxetine, with the tricyc-
lic antidepressant, amitriptyline); the remainder used
medications that are used infrequently, such as dothie-
pin and trimipramine, or Chinese herbal remedies. Only
1 trial evaluated non-pharmacological approaches alone,
with another assessing a combination of drug and
psychological interventions. Overall, a trend towards
efficacy was observed with active pharmacological
treatments (standardised mean difference − 0.49; 95% CI
-1.07 to 0.10), although this was not significant, and
significant heterogeneity was observed between study
estimates. The one trial of a psychological intervention
(randomising 30 patients to cognitive behavioural
therapy, and 29 patients to usual care) reported no sta-
tistically significant effect on depressive symptoms [79].
Overall, the level of evidence identified by this review
was only low-to-moderate, and further research is
required before more definitive conclusions can be made
regarding pharmacological and non-pharmacological
interventions to manage depression and anxiety in RA.
Patient perspectives on management approaches
Qualitative research suggests that patients with RA and
comorbid anxiety and depression would favour the use
of psychological, over pharmacological interventions.
Machin et al. interviewed patients with RA who
responded positively to the case-finding questions for
anxiety and/or depression (using GAD-2 and/or
PHQ-2), to explore their perspectives on this issue [80].
This was conducted in one clinic in England. In the
quantitative part of the study 171 patients attending a
nurse-led annual review clinic completed the question-
naire; scores in 28% suggested they were anxious or
depressed. Fourteen of the patients participated in the
qualitative study. They were predominantly white
women (68%) reflecting the ethnicity of the local popula-
tion and the prevalence of RA in females; their average
was 63 years and the majority were retired. Patients with
mental health problems felt considerable shame and
stigma mentioning them to their clinicians. Whereas
some participants were open to pharmacological
treatments, others feared potential drug interactions, or
perceived that medication was offered as a “quick fix”.
Overall, participants expressed a preference for psycho-
logical therapies, although several reported difficulties
accessing such care.
This preference for psychological treatments was
replicated in a study exploring 46 US Hispanic patients’
perspectives of depression associated with RA. Patients
Fig. 2 Stepped Care Approach to Managing Depression and Anxiety in Adults (based on NICE guidelines). CBT = cognitive behavioural therapy;
GAD = generalised anxiety disorder. Figure produced using information provided in NICE guidelines for managing depression in adults [54] and
adults with a chronic physical health problem [75], alongside guidelines for managing generalised anxiety disorder in adults [53]
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often perceived antidepressants to be unnecessary or
associated with side-effects, with a preference expressed
for interventions incorporating an interpersonal compo-
nent, such as support groups [81]. A third study, which
represented a survey of 2280 patients with inflammatory
arthritis that focussed on exploring patient views on
their psychological support, also identified a substantial
demand for psychological interventions [82]. Of the
1210 respondents, approximately two-thirds reported
that they would use a self-management/coping clinic if
the service were offered.
Despite these patient preferences, rheumatology units
within England self-report a lack of access to psycho-
logical support. A postal survey to rheumatology units
in 143 acute trusts across England highlighted this issue.
Of the respondents, 73% rated their unit’s psychological
support provision as being “inadequate”, despite most
feeling that psychological support fell within their remit
[83]. Barriers to providing psychological support
included clinical time constraints, a lack of available
training, alongside delivery costs.
Fatigue
Definition
Fatigue is defined as a state of exhaustion and decreased
strength accompanied by a feeling of weariness, sleepi-
ness, and irritability, with a cognitive component [84]. It
is unrelated to energy expenditure, and does not im-
prove with rest.
Prevalence in RA
Fatigue is an extremely common symptom in RA. In the
Quantitative Standard monitoring of Patients with RA
(QUEST-RA) study (evaluating 9874 patients, across 34
countries) high levels of fatigue (defined as a Fatigue
VAS of > 6.6 units) were found in almost 1 in 4 patients
[85]. A recent systematic review of RA-fatigue aetiology
reported that amongst 121 studies (totalling > 100,000
patients with RA) the mean fatigue score (on a normal-
ised scale ranging from 0 (no fatigue) to 1.0 (worst
possible fatigue)) was 0.5 units [86].
Aetiology of fatigue in RA
The aetiology of fatigue in RA appears multifactorial.
Hewlett et al. proposed a conceptual model for
RA-related fatigue, to facilitate research into causal path-
ways and interventions. This conceptual model has three
core, interacting components: [1] the RA disease process
(RA), [2] thoughts, feelings and behaviours (cognitive,
behavioural) and [3] personal life issues (personal) [87].
An overview of the key proposed factors in each of these
components is provided in Fig. 3. This conceptual model
highlights the substantial interaction that is considered
to occur between fatigue, pain and disability.
Since the publication of this conceptual model, several
systematic reviews have assessed factors associated with
RA-fatigue. A recent systematic review of 121 studies,
by Madsen et al.., reported positive associations between
fatigue and pain, CRP, ESR and DAS28. They also
reported that high levels of fatigue occurred even in
patients with well controlled disease [86]. An earlier sys-
tematic review of 25 studies by Nikolaus et al, reported
that the relationship between fatigue and many variables
is uncertain, with conflicting evidence observed across
studies (particularly with regards to characteristics of in-
flammatory activity) [88]. However, the most convincing
evidence for a relationship with fatigue was observed for
pain, disability, and depression.
Assessing fatigue
There are multiple methods to measure fatigue in RA,
which have previously been reviewed in detail by
Hewlett and colleagues in two reviews [87, 89]. We have
provided a summary of some key methods in Table 2.
As with assessing pain, the quickest and simplest way to
measure fatigue, and therefore the method that may be
preferable to use in routine care, is using a VAS (scoring
0 to 100, with higher scores indicating greater fatigue).
As with the pain VAS, as it is a unidimensional measure
it cannot fully capture the multidimensional nature of
patients’ fatigue.
Treatment
Given the multifactorial nature of RA-fatigue, interven-
tions should be multifaceted and directed towards
factors which may be exacerbating fatigue, such as pain
or mood disturbance, in individual patients.
Although the relationship between disease activity
and fatigue is complex, evidence suggests that bio-
logic drugs do reduce fatigue. A systematic review by
Almeida et al assessing the impact of biologic agents
(20 TNF-inhibitors, and 12 non-TNF-inhibitors) on
fatigue reported that biologics in patients with active
RA can lead to small-to-moderate improvements in
fatigue, with similar magnitudes of effect observed for
both TNF-inhibitors and other biologic agents [90].
The authors concluded, however, that “it is unclear
whether the improvement results from a direct action
of the biologics on fatigue, or indirectly through re-
duction in inflammation, disease activity or some
other mechanism”. More recently, similar modest ef-
fects on reducing fatigue have been reported with the
Janus Kinase inhibitor, baricitinib [91].
A Cochrane systematic review of 24 studies examining
non-pharmacological interventions for fatigue by Cramp
et al found small but statistically significant benefits of
both physical activity interventions and psychosocial in-
terventions [92]. Another systematic review by Kelley et
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al of aerobic exercise as a treatment for RA-fatigue,
suggested that whilst land-based aerobic exercise is asso-
ciated with statistically significant reductions in fatigue,
it is unlikely that large numbers of people would obtain
clinically-relevant reductions [93]. They based their
conclusion on changes in relation to the minimal
important difference effect size and recommended
cut-points. At the same time land-based aerobic exercise
did not appear to increase fatigue and is safe; therefore,
overall it is likely to be beneficial as part of the overall
management of RA.
There is a resource implication in implementing many
of these physical or cognitive behavioural approaches,
which will limit their uptake within routine clinical care.
A simple, more implementable approach to increasing ex-
ercise to target fatigue is the use of wearable-technology,
such as pedometers. A clinical trial by Katz et al, suggested
that this approach is effective in RA. In this trial, 96
patients were randomised to receive either education
alone (control group), or a pedometer with step-monitor-
ing diary, with or without step targets. Both intervention
groups had significantly higher activity levels and greater
reductions in fatigue at 21-weeks compared with the
control group [94]. Overall the balance of evidence is
strongly in favour of recommending RA patients exer-
cise regularly to limit their fatigue. Although by itself
it is unlikely to resolve this feature entirely, it is safe,
effective and inexpensive and can be combined with
other approaches.
Muscle loss and RA Cachexia
Definition
There are two types of cachexia that can occur in
patients with RA. The first is the “classic” low body mass
index (BMI) form, in which patients with severe
systemic disease lose both muscle mass and fat mass,
Fig. 3 Conceptual Model for RA-Related Fatigue Proposed by Hewlett et al [87]. Figure produced using concepts reported by Hewlett et al [87]
Table 2 Key methods to assess fatigue in patients with rheumatoid arthritis
Measure Population Content Completion time
(minutes)
Scoring time
(minutes)
Bristol RA
Fatigue Multi-Dimensional
Questionnaire (BRAF MDQ) [125]
Adults with RA 20 items cover domains of physical fatigue, living with
fatigue, cognitive fatigue, and emotional fatigue.
5 3
Bristol RA
Fatigue Numerical Rating
Scales (BRAF NRS) For Severity,
Effect, And Coping [125]
Adults with RA 3 single-item numeric rating scales on fatigue severity,
effect on patients’ lives, and coping with fatigue.
1 1
Fatigue Visual Analogue Scale [89] Any adult
population
Usually one horizontal line, measuring 10 cm, anchored
with verbal descriptors such as “not at all tired” and
“very tired”.
< 1 < 1
Functional Assessment Chronic
Illness Therapy (Fatigue) (FACIT-F)
[126]
Adults with chronic
illness
13 items covering physical fatigue, functional fatigue,
emotional fatigue, and social consequences of fatigue.
4 4
Multi-Dimensional Assessment of
Fatigue [127]
Adults with RA 15 items covering 4 dimensions of fatigue: severity,
distress, interference in activities of daily living, and
frequency and change during past week.
8 5
Short-Form 36 Vitality [124] Any adult
population
A 4-item scale covering energy and fatigue. 1 1
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leading to an emaciated appearance [95]. The second is
“RA cachexia” in which muscle mass is low, but is
compensated for by a gain in body fat.
Aetiology
Patients can lose muscle mass for several reasons, in-
cluding malnutrition, starvation, cachexia and sarcope-
nia. Malnutrition and starvation are simple concepts
related to insufficient food intake. Sarcopenia is predom-
inantly age-related skeletal muscle loss, and is conse-
quently often considered to be a geriatric syndrome [96].
In contrast, cachexia is the consequence of a long-term
systemic inflammatory response. The key feature of
cachexia is the redistribution of protein content, with
skeletal muscle depleted of proteins and an increase in
the synthesis of proteins related to the acute-phase
response. RA cachexia is considered to be driven by the
overproduction of cytokines and inflammation [97],
with these metabolic changes of cachexia being
cytokine-regulated [98]. RA cachexia has been linked
to the metabolic syndrome, with associated abnormal-
ities in lipid levels [99]. Patients with RA cachexia
have abnormal energy and protein metabolism and in-
creased inflammatory cytokine production including
interleukin-1 and tumour necrosis factor [100].
Prevalence
In RA, there are marked variations in the reported
prevalence of cachexia. Some experts suggest it is very
common, occurring in as many as two-thirds of patients
with RA [101]. Other experts have drawn different con-
clusions, and suggest it is relatively rare and only occurs
in approximately 1% of patients [102]. It is likely that
these differences are driven by the use of diverse criteria
to define the presence of RA cachexia, with different
studies using different definitions, based on varying fat
and muscle mass cut-offs [99, 103]. Overall, however,
classic cachexia is considered rare, and easily identifi-
able, and RA cachexia, is considered more common
although it is not readily identified by patients and
clinicians owing to the presence of a normal, or even
increased, BMI [95].
Methods of assessment
Measuring weight and height provide useful information
in many settings but are insufficient to assess muscle
mass, which is needed to evaluate the presence of RA
cachexia. Early studies used a variety of approaches to
assess cachexia including energy expenditure profiles
and whole body protein turnover [100]. The accurate
assessment of cachexia in RA depends upon being able
to define the amount of lean body mass, and fat mass
that is present. Whole body imaging using computerised
tomography and magnetic resonance imaging can
achieve this goal but their use in large numbers of pa-
tients is impractical. Dual-energy X-ray absorptiometry,
which is widely used to assess bone density in RA, is a
reliable and established method for examining the
composition of body soft tissue and determining how
much is fat and how much is lean mass. It is, therefore,
potentially valuable in larger clinical studies of RA
cachexia, though it is not currently used for this evalu-
ation in routine practice [104]. A simpler alternative is
bioelectrical impedance analysis, which can accurately es-
timate body composition, particularly the amount of body
fat. It determines the electrical impedance, or opposition
to the flow of an electric current, through body tissues.
This allows an assessment of the total body water, which
can be used to estimate fat-free body mass and, by differ-
ence with body weight, the amount of body fat. It has
been successfully employed in RA patients and is likely to
be particularly useful in epidemiological studies [105].
Impact
The loss of lean body mass, a key component of RA
cachexia, has been shown across several studies to
strongly associate with the presence of disability. Engvall
et al. reported that within 60 patients with RA, the cor-
relation coefficient between lean body mass and HAQ
scores was − 0.42 (P = 0.001) [103]. Other studies have
also reported significant associations between loss of
lean body mass and disability [106, 107]. The balance of
evidence suggests that cachexia causes disability, but
there are complex interactions between RA cachexia,
sedentary lifestyles and disability in patients with RA.
There is a growing body of evidence that sedentary
behaviour, which means too much sitting as opposed to
movement and exercise, may drive persisting inflamma-
tory disease and elements of cachexia in RA [108].
RA cachexia is often considered to have detrimental im-
pacts on cardiovascular health, although this issue appears
controversial. Summers et al [95] have reviewed this rela-
tionship in detail, and they identified two studies reporting
the association between RA cachexia and cardiovascular
disease [99, 109]. The findings of these studies depended
on the cut-offs of fat and muscle mass used to define
rheumatoid cachexia. Taking a fat free mass index below
the 25th percentile and fat mass index above the 50th per-
centile of a reference population, Elkan et al reported that
within 80 patients with RA, 18% of women and 26% of
men had “rheumatoid cachexia” and that these individuals
had significantly higher total cholesterol and low density
lipoprotein, alongside a higher frequency of hypertension
and metabolic syndrome [99]. In contrast, using the same
definition applied to 400 patients with RA, Metsios et al.
reported no significant differences in cardiovascular risk
factors, or established cardiovascular disease between
patients with and without RA cachexia [109].
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Treatment
As cytokines are implicated in the development of RA
cachexia there has been considerable interest in evaluating
whether cytokine inhibition can improve it. Two small
studies evaluated this possibility. One represented a retro-
spective comparison of 20 RA cases receiving tumour ne-
crosis factor inhibitors and 12 matched controls. Over
12 weeks, biologics improved disease activity and physical
function but there were no significant changes in resting
energy expenditure and fat-free body mass [110]. The
other study was a small 6-month trial of etanercept in 26
patients with early RA; it provided no substantial evidence
that this treatment had an important impact on cachexia,
though there was some evidence that biologic treatment
normalised the anabolic response to overfeeding in a mi-
nority of patients [111]. This finding implies that instead
of excess food intake resulting in increases in body fat,
lean body tissue is preferentially formed in these patients.
A larger study of 82 patients subsequently evaluated the
impact of tight control using treat-to-target approaches. It
also found no evidence that this approach improved RA
cachexia [112].The balance of evidence from these small
studies is that inhibiting cytokines and controlling syno-
vitis has little impact on RA cachexia, which requires an
alternative management strategy.
The impact of exercise appears more positive. An ini-
tial small observational study of three months’ progres-
sive resistance training as an adjunctive treatment for
rheumatoid cachexia in 10 RA patients with matched
controls showed it was effective and safe for stimulating
muscle growth [113]. A subsequent trial of 28 patients
with established, controlled disease showed six months’
weekly progressive resistance training was both safe and
effective in restoring lean mass and function in these pa-
tients [114]. Follow-up of some of these patients at three
years showed that stopping the resistance training and
resuming normal activity resulted in loss of the benefits
of progressive resistance training on lean mass and
strength-related function. However, there was substantial
retention of the benefits of reduced fat mass and walking
ability [115]. Recent research has shown that a short
six-week treatment using progressive resistance training
can be readily achieved within routine care settings and
that this approach is beneficial for patients [116]. The
balance of current evidence favours this approach to
treat RA cachexia.
Assessing these extra-articular impacts in routine care
Pain, depression and anxiety, fatigue, and rheumatoid
cachexia are important issues that would benefit from
assessment and management in a routine clinic setting.
Delivering this will be challenging, as there are already
extensive time pressures in delivering the standard T2T
approach. However, the growing use of electronic
medical records, and digital technologies to capture
PROs (reports of patients’ health that come directly from
the patient and are measured using standardised, vali-
dated questionnaires [117]) that “feed forward” into
these, may make this achievable within current medical
resources. Although such PROs would not be able to
directly identify patients with rheumatoid cachexia, they
would identify patients with functional impairment likely
to benefit from exercise therapy, which in turn would
help improve any co-existing cachexia.
Such an approach, in a rheumatology context, has
been pioneered by the Swedish Rheumatology Quality
Registry [118]. Patients with rheumatic diseases (includ-
ing RA) attending a number of clinics across Sweden are
able to complete a self-administered health survey prior
to their clinic review. This can be undertaken at their
routine clinic review using a touch-screen computer in
the waiting room area, or at home/work via a secure
internet web portal. Patients enter data on a range of
PROs, covering general well-being, pain, activities of
daily living, quality of life, and ability to work. These
patient reported data are then “fed-forward” into their
electronic medical records, and summarised in a
summary overview “dashboard”, which trends their
PROs and clinician-reported outcomes over time.
During their clinic appointment, the clinician and
patient review the co-produced dashboard information
together, decide on the next treatment steps, and print
an updated summary overview for the patient to bring
home. A questionnaire and qualitative interviews of a
subset of patients and clinicians confirmed this system
to be acceptable, and useful, with 96% of patients rating
their “overall impression of the system” as “excellent” or
“very good” [119]. A similar approach is being under-
taken at the University of Manchester, using a mobile
phone application (the Remote Monitoring of RA (RE-
MORA) app), which allows patients to log daily symp-
toms of their RA and its impact between clinic
appointments; these data are sent directly to their elec-
tronic healthcare records [120]. Positive feedback was
gained from patients in preliminary testing, who felt that
it made care “more personal to you”, and easier to have
a “shared conversation” with the clinician [121]. Add-
itionally, a high-level of data completeness was obtained
over a 3-month period of testing [122]. Further research
in this area is required, with key questions including
which PROs should be measured in a routine NHS
setting, how the information should be presented to
patients and clinicians, and what management should be
undertaken for identified problems.
Conclusions
The evidence outlined in this review has demonstrated
that pain, anxiety and depression, fatigue, and muscle
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loss, are highly prevalent problems in patients with RA.
Whilst T2T has revolutionised the overall health and
outcomes of patients with RA, it does not directly
address these important extra-articular impacts, which
can persist despite attaining remission. This suggests
that these symptoms are likely to benefit from a more
targeted management approach, which is used alongside
T2T. This is in-line with patients’ preferences, with ad-
dressing pain being a key treatment goal across a broad
range of patient surveys.
Research suggests that pain, mental health, and fatigue
are inter-related problems, that share overlapping aetiol-
ogies. As such, they are likely to benefit from a holistic
assessment strategy and treatment approach. As detailed
in this review, there is evidence to support the use of
non-pharmacological strategies, such as psychological
interventions and specific forms of exercise to address
these issues, with the latter also benefiting muscle loss.
Although these interventions have, on the whole,
small-to-modest clinical gains, if they are used in
combination, and tailored to individual patients, their
efficacy is likely to be optimised.
There are many challenges in delivering such a “holis-
tic care” approach to patients. Key barriers include a lack
of access to psychological services (with nearly three-
quarters of rheumatology units in England self-rating
their access to psychological support as being “inad-
equate”), time constraints in clinic (with follow-up
appointments generally lasting 15 min), financial con-
straints within the NHS, alongside uncertainty as to who
should be undertaking this (primary or secondary care
clinicians).
Further research is required to clarify the optimal way
to address these extra-articular impacts in routine care.
This needs to not only focus on how to manage these is-
sues, but also how they can be assessed within a brief
clinic appointment. It is likely that digital technologies
will play an important role in this area, enabling PRO
data to be collected electronically and populated into pa-
tients’ electronic health care records. Although there is a
risk of overwhelming clinicians with information in the
short-term, clinical practice should rapidly adjust to in-
corporate this additional data. A focus on improving
co-ordination of care across the primary-secondary care
interface is also needed, to ensure that rheumatologists
and community services with expertise in managing
mental health, are working together in an optimal
manner, for the good of patients.
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